ASCO Lung Cancer
Conference Coverage
Nasal swab test helps identify malignant lung nodules
The test is based on “field of injury” technology, which examines genomic changes in the lining of the respiratory tract for evidence of cancer...
Latest News
Urine metabolites could predict end of life in lung cancer
Conference Coverage
Vinorelbine survival benefit in mesothelioma overshadowed by advances in immuno-oncology
Conference Coverage
KRAS inhibitor improved survival in phase 2 lung cancer trial
Conference Coverage
Community practice lung cancer patients insufficiently tested for treatment-related biomarkers
Conference Coverage
NSCLC: Immune-related AEs during checkpoint inhibitor therapy may predict outcomes
Conference Coverage
Immunotherapy takes first major step into earlier NSCLC
Conference Recap
Highlights in Non–Small Cell Lung Cancer From ASCO 2020
Dr. Mark Kris reports on key studies in NSCLC from ASCO 2020, including the practice-changing ADAURA trial, results on an antibody‒...
Conference Coverage
Immunotherapy combo improves ORR, PFS in PD-L1+ NSCLC
Adding tiragolumab to atezolizumab led to “clinically meaningful” improvements in patients with PD-L1–positive non–small cell lung cancer.
Clinical Insights
CheckMate 9LA: ‘Doing better’ for stage IV/recurrent NSCLC
Dr. Alan P. Lyss explores the clinical implications of the CheckMate 9LA study.
Conference Coverage
‘Hospital at home’ cuts ED visits and costs for cancer patients
An oncology hospital-at-home model was associated with a reduction in hospitalizations, emergency department visits, and costs.